Cogent Biosciences IncNASDAQ:COGT
- LAST PRICE9.5200
- TODAY'S CHANGE (%)0.3000 (3.2538%)
- Bid / Lots9.1000/ 1
- Ask / Lots9.5800/ 3
- Open / Previous Close9.4100 / 9.2200
- Day Range
- 52 Week Range
- Volume417,715
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | COGT |
|---|---|---|
| 09:32 ET | 6424 | 9.26 |
| 09:36 ET | 1000 | 9.39 |
| 09:38 ET | 471 | 9.41 |
| 09:41 ET | 800 | 9.41 |
| 09:43 ET | 200 | 9.385 |
| 09:45 ET | 211 | 9.385 |
| 09:48 ET | 400 | 9.41 |
| 09:50 ET | 800 | 9.43 |
| 09:52 ET | 600 | 9.42 |
| 09:54 ET | 1305 | 9.43 |
| 09:56 ET | 2243 | 9.5 |
| 09:57 ET | 200 | 9.53 |
| 09:59 ET | 701 | 9.47 |
| 10:01 ET | 4751 | 9.45 |
| 10:03 ET | 865 | 9.45 |
| 10:06 ET | 100 | 9.45 |
| 10:08 ET | 900 | 9.43 |
| 10:10 ET | 500 | 9.42 |
| 10:12 ET | 600 | 9.43 |
| 10:14 ET | 300 | 9.41 |
| 10:15 ET | 350 | 9.4 |
| 10:19 ET | 300 | 9.39 |
| 10:21 ET | 600 | 9.35 |
| 10:24 ET | 300 | 9.35 |
| 10:26 ET | 1857 | 9.35 |
| 10:28 ET | 900 | 9.38 |
| 10:30 ET | 600 | 9.33 |
| 10:32 ET | 400 | 9.31 |
| 10:33 ET | 2185 | 9.34 |
| 10:35 ET | 326 | 9.36 |
| 10:37 ET | 427 | 9.37 |
| 10:39 ET | 2100 | 9.33 |
| 10:42 ET | 1631 | 9.36 |
| 10:44 ET | 200 | 9.37 |
| 10:46 ET | 677 | 9.34 |
| 10:50 ET | 444 | 9.34 |
| 10:51 ET | 2961 | 9.23 |
| 10:55 ET | 100 | 9.21 |
| 10:57 ET | 1874 | 9.26 |
| 11:00 ET | 106 | 9.28 |
| 11:02 ET | 100 | 9.25 |
| 11:06 ET | 300 | 9.265 |
| 11:08 ET | 100 | 9.25 |
| 11:11 ET | 100 | 9.265 |
| 11:13 ET | 750 | 9.26 |
| 11:15 ET | 638 | 9.24 |
| 11:20 ET | 100 | 9.235 |
| 11:22 ET | 300 | 9.24 |
| 11:24 ET | 800 | 9.24 |
| 11:26 ET | 100 | 9.26 |
| 11:27 ET | 200 | 9.27 |
| 11:31 ET | 300 | 9.27 |
| 11:36 ET | 300 | 9.28 |
| 11:40 ET | 1200 | 9.305 |
| 11:44 ET | 757 | 9.31 |
| 11:45 ET | 2310 | 9.34 |
| 11:47 ET | 736 | 9.34 |
| 11:49 ET | 102 | 9.36 |
| 11:54 ET | 100 | 9.37 |
| 11:56 ET | 741 | 9.36 |
| 11:58 ET | 220 | 9.35 |
| 12:00 ET | 150 | 9.35 |
| 12:02 ET | 100 | 9.35 |
| 12:05 ET | 200 | 9.34 |
| 12:07 ET | 366 | 9.34 |
| 12:14 ET | 701 | 9.325 |
| 12:16 ET | 200 | 9.325 |
| 12:20 ET | 200 | 9.31 |
| 12:23 ET | 100 | 9.3 |
| 12:25 ET | 100 | 9.26 |
| 12:27 ET | 536 | 9.27 |
| 12:32 ET | 100 | 9.27 |
| 12:34 ET | 100 | 9.26 |
| 12:36 ET | 400 | 9.25 |
| 12:38 ET | 100 | 9.23 |
| 12:39 ET | 700 | 9.24 |
| 12:41 ET | 1840 | 9.26 |
| 12:43 ET | 596 | 9.3 |
| 12:50 ET | 620 | 9.29 |
| 12:52 ET | 200 | 9.27 |
| 12:56 ET | 550 | 9.29 |
| 12:57 ET | 300 | 9.29 |
| 12:59 ET | 800 | 9.285 |
| 01:01 ET | 200 | 9.285 |
| 01:03 ET | 6555 | 9.36 |
| 01:06 ET | 676 | 9.37 |
| 01:10 ET | 401 | 9.35 |
| 01:14 ET | 100 | 9.35 |
| 01:17 ET | 100 | 9.34 |
| 01:21 ET | 200 | 9.33 |
| 01:24 ET | 500 | 9.34 |
| 01:26 ET | 100 | 9.33 |
| 01:28 ET | 100 | 9.34 |
| 01:30 ET | 1122 | 9.36 |
| 01:32 ET | 334 | 9.35 |
| 01:33 ET | 200 | 9.34 |
| 01:35 ET | 1093 | 9.295 |
| 01:37 ET | 200 | 9.28 |
| 01:42 ET | 564 | 9.31 |
| 01:46 ET | 1927 | 9.34 |
| 01:48 ET | 300 | 9.37 |
| 01:50 ET | 700 | 9.36 |
| 01:51 ET | 200 | 9.35 |
| 01:55 ET | 200 | 9.35 |
| 02:00 ET | 100 | 9.37 |
| 02:02 ET | 100 | 9.37 |
| 02:04 ET | 708 | 9.4 |
| 02:06 ET | 405 | 9.39 |
| 02:08 ET | 200 | 9.38 |
| 02:11 ET | 100 | 9.39 |
| 02:13 ET | 400 | 9.405 |
| 02:15 ET | 200 | 9.4 |
| 02:20 ET | 1416 | 9.385 |
| 02:22 ET | 200 | 9.38 |
| 02:24 ET | 100 | 9.37 |
| 02:26 ET | 700 | 9.38 |
| 02:27 ET | 300 | 9.38 |
| 02:29 ET | 200 | 9.37 |
| 02:31 ET | 200 | 9.37 |
| 02:33 ET | 200 | 9.37 |
| 02:36 ET | 200 | 9.37 |
| 02:38 ET | 342 | 9.37 |
| 02:40 ET | 100 | 9.37 |
| 02:42 ET | 1136 | 9.36 |
| 02:44 ET | 1148 | 9.37 |
| 02:45 ET | 300 | 9.37 |
| 02:49 ET | 1250 | 9.4 |
| 02:51 ET | 150 | 9.41 |
| 02:54 ET | 100 | 9.39 |
| 02:56 ET | 200 | 9.405 |
| 02:58 ET | 200 | 9.39 |
| 03:00 ET | 100 | 9.4015 |
| 03:02 ET | 710 | 9.39 |
| 03:05 ET | 100 | 9.38 |
| 03:07 ET | 2085 | 9.37 |
| 03:09 ET | 755 | 9.43 |
| 03:12 ET | 152 | 9.42 |
| 03:14 ET | 200 | 9.41 |
| 03:16 ET | 100 | 9.41 |
| 03:18 ET | 2550 | 9.38 |
| 03:20 ET | 200 | 9.37 |
| 03:21 ET | 942 | 9.4 |
| 03:23 ET | 1926 | 9.435 |
| 03:25 ET | 2676 | 9.46 |
| 03:27 ET | 100 | 9.45 |
| 03:30 ET | 550 | 9.43 |
| 03:32 ET | 1400 | 9.43 |
| 03:34 ET | 1105 | 9.43 |
| 03:36 ET | 403 | 9.43 |
| 03:38 ET | 365 | 9.44 |
| 03:39 ET | 700 | 9.44 |
| 03:41 ET | 1946 | 9.47 |
| 03:43 ET | 791 | 9.47 |
| 03:45 ET | 2316 | 9.49 |
| 03:48 ET | 2319 | 9.48 |
| 03:50 ET | 1961 | 9.49 |
| 03:52 ET | 4199 | 9.49 |
| 03:54 ET | 5298 | 9.5175 |
| 03:56 ET | 13967 | 9.51 |
| 03:57 ET | 6994 | 9.56 |
| 03:59 ET | 167147 | 9.52 |
Jun 27, 2024
DJ Cogent Biosciences Price Target Maintained With a $18.00/Share by Needham, from 11:54AM ET on Thursday Jun 27, 2024 by Dow Jones
11:54AM ET on Thursday Jun 27, 2024 by Dow JonesCogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial, from 8:00AM ET on Thursday Jun 27, 2024 by Dow Jones
8:00AM ET on Thursday Jun 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cogent Biosciences Inc | 881.6M | -3.8x | --- |
Nuvation Bio Inc | 912.1M | -11.9x | --- |
Perspective Therapeutics Inc | 917.7M | -8.4x | --- |
Lexicon Pharmaceuticals Inc | 842.2M | -2.9x | --- |
Olema Pharmaceuticals Inc | 821.7M | -7.7x | --- |
89Bio Inc | 950.4M | -4.6x | --- |
Company Information
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Contact Information
- Headquarters
- 275 Wyman Street, 3Rd FloorWALTHAM, MA, United States 02451
- Phone
- 617-945-5576
- Fax
- ---
Executives
- Independent Chairman of the Board
- Peter Harwin
- Chief Executive Officer, President, Director
- Andrew Robbins
- Chief Financial Officer
- John Green
- Chief Scientific Officer
- John Robinson
- Chief Commercial Officer
- Cole Pinnow
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $881.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 95.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.71 |
EPS | $-2.47 |
Book Value | $2.99 |
P/E Ratio | -3.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
